BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry 2018;17:19. [PMID: 29760763 DOI: 10.1186/s12991-018-0190-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2015;10:49-62. [PMID: 25945081 DOI: 10.2147/CE.S54075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
3 Sun B, Lv Y, Xu H, Qi C, Li C, Liu P. Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus. Exp Ther Med 2020;20:2895-902. [PMID: 32765787 DOI: 10.3892/etm.2020.9026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Neri G, Serrati C, Zolo P, Cataldo N, Ripellino C. Italian neurologists' perception on cognitive symptoms in major depressive disorder. Neurol Sci 2016;37:1437-42. [PMID: 27155852 DOI: 10.1007/s10072-016-2601-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
7 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]